drugset / Trial / NCT07047209

Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)

NCT07047209

Phase 2 Active not recruiting 40 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.

Timeline

Start
2025-05-27
Primary completion
2026-03
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 62.5 ug Oral
Subject Digoxin Other / unclassified 125 ug Oral
Subject Digoxin Other / unclassified 250 ug Oral